Aribio's AR1001 Achieves Primary Goal in Phase 3 Trial, No Difference in Overall Patient Group


Aribio's oral Alzheimer's treatment candidate, AR1001 (ingredient name mirodenafil), has achieved its primary evaluation goal in a global Phase 3 clinical trial. The drug demonstrated effectiveness in a group that did not take existing dementia medications. This finding is significant as it confirms the potential of an oral drug in a market primarily dominated by injectable treatments.

On November 16, during the Clinical Trials on Alzheimer's Disease (CTAD 2026) conference in Boston, Aribio presented the 52-week results of the global Phase 3 trial (POLARIS-AD) for AR1001. The trial involved 1,535 early Alzheimer's patients from 13 countries, who took either 30 mg of AR1001 or a placebo once daily for 52 weeks.

The trial was designed to evaluate two groups: the overall patient population and a subgroup of 604 patients who were not taking existing dementia medications. Achieving statistical significance in either group would fulfill the primary goal. In the subgroup, patients receiving AR1001 experienced a 0.44-point smaller decline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score compared to the placebo group, indicating a 31% slowdown in disease progression.

However, the overall patient group showed only a 0.11-point difference, failing to achieve statistical significance. Secondary endpoints, including cognitive function, also did not show meaningful differences between the two groups. The incidence of serious adverse events was similar, with 10.0% in the treatment group and 9.8% in the placebo group.

These results are directly linked to commercialization efforts. In May, Aribio signed a $4.74 billion global exclusive option agreement for AR1001 with China's Puxing Pharmaceutical, covering major markets including the U.S., Europe, and Japan, excluding South Korea, the Middle East, and Latin America.

However, the inability to demonstrate efficacy in the overall patient group remains a challenge. Industry experts believe Aribio will pursue regulatory approval based on the results from the subgroup. The key question will be whether regulatory authorities will grant approval based solely on these findings.





* This article has been translated by AI.